Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-1980
Abstract: Chronic Myeloid Leukemia (CML) is largely caused by the Philadelphia (Ph) chromosome carrying the Break point Cluster Region-Abelson (BCR-ABL) oncogene. Imatinib is a BCR-ABL-targeted therapy and considered the standard of care in CML management. Resistance… read more here.
Keywords: bcr abl; resistance; t315i; baf3 ... See more keywords
Novel CD33 Antibodies Unravel Localization, Biology, and Therapeutic Implications of CD33 Isoforms
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-122596
Abstract: Background: Recent promising results from the CD33-directed immunoconjugate, gemtuzumab ozogamicin (GO), has transformed the realm of acute myeloid leukemia (AML) treatment strategies and has opened the door for several other CD33-directed immunotherapeutic strategies to be… read more here.
Keywords: biology; cd33d2 isoform; cd33; baf3 ... See more keywords